Moody Aldrich Partners LLC Acquires New Holdings in AnaptysBio, Inc. (NASDAQ:ANAB)

Moody Aldrich Partners LLC acquired a new stake in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 83,224 shares of the biotechnology company's stock, valued at approximately $1,547,000. Moody Aldrich Partners LLC owned 0.27% of AnaptysBio as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the company. HighMark Wealth Management LLC purchased a new stake in shares of AnaptysBio during the first quarter valued at approximately $1,710,000. Farther Finance Advisors LLC raised its stake in shares of AnaptysBio by 9,778.9% during the first quarter. Farther Finance Advisors LLC now owns 1,877 shares of the biotechnology company's stock valued at $35,000 after purchasing an additional 1,858 shares during the period. Rhumbline Advisers raised its stake in shares of AnaptysBio by 2.7% during the first quarter. Rhumbline Advisers now owns 30,903 shares of the biotechnology company's stock valued at $574,000 after purchasing an additional 826 shares during the period. GAMMA Investing LLC purchased a new stake in shares of AnaptysBio during the first quarter valued at approximately $113,000. Finally, Wellington Management Group LLP raised its stake in shares of AnaptysBio by 0.8% during the fourth quarter. Wellington Management Group LLP now owns 66,467 shares of the biotechnology company's stock valued at $880,000 after purchasing an additional 528 shares during the period.

Insider Buying and Selling

In other news, Director Hollings Renton sold 20,925 shares of the business's stock in a transaction on Wednesday, July 2nd. The shares were sold at an average price of $23.57, for a total transaction of $493,202.25. Following the completion of the transaction, the director owned 4,965 shares of the company's stock, valued at approximately $117,025.05. The trade was a 80.82% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 33.50% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on ANAB. Guggenheim reissued a "buy" rating and set a $90.00 price target (up previously from $54.00) on shares of AnaptysBio in a research report on Wednesday, May 28th. HC Wainwright raised shares of AnaptysBio from a "neutral" rating to a "buy" rating and raised their price target for the stock from $22.00 to $38.00 in a research report on Wednesday, June 4th. Johnson Rice reissued a "buy" rating on shares of AnaptysBio in a research report on Wednesday, March 26th. Finally, Wedbush reissued an "outperform" rating and set a $40.00 price target on shares of AnaptysBio in a research report on Thursday, May 29th. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $42.38.

AnaptysBio Trading Down 1.3%

AnaptysBio stock traded down $0.30 during mid-day trading on Monday, reaching $23.45. The company's stock had a trading volume of 448,281 shares, compared to its average volume of 642,332. The firm has a market cap of $688.96 million, a price-to-earnings ratio of -4.84 and a beta of -0.27. The business has a 50 day moving average price of $21.93 and a 200-day moving average price of $18.64. AnaptysBio, Inc. has a twelve month low of $12.21 and a twelve month high of $41.31.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The biotechnology company reported ($1.28) EPS for the quarter, topping analysts' consensus estimates of ($1.30) by $0.02. The firm had revenue of $27.77 million during the quarter, compared to the consensus estimate of $15.27 million. AnaptysBio had a negative net margin of 125.70% and a negative return on equity of 282.47%. On average, equities analysts expect that AnaptysBio, Inc. will post -6.08 EPS for the current fiscal year.

AnaptysBio declared that its Board of Directors has initiated a stock repurchase plan on Monday, March 24th that permits the company to buyback $75.00 million in shares. This buyback authorization permits the biotechnology company to buy up to 13.1% of its shares through open market purchases. Shares buyback plans are usually an indication that the company's board believes its stock is undervalued.

AnaptysBio Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.